Discovery and Optimization of Neutralizing SARS-CoV-2 Antibodies Using ALTHEA Gold Plus Libraries™

Int J Mol Sci. 2023 Feb 27;24(5):4609. doi: 10.3390/ijms24054609.

Abstract

We recently reported the isolation and characterization of anti-SARS-CoV-2 antibodies from a phage display library built with the VH repertoire of a convalescent COVID-19 patient, paired with four naïve synthetic VL libraries. One of the antibodies, called IgG-A7, neutralized the Wuhan, Delta (B.1.617.2) and Omicron (B.1.1.529) strains in authentic neutralization tests (PRNT). It also protected 100% transgenic mice expressing the human angiotensin-converting enzyme 2 (hACE-2) from SARS-CoV-2 infection. In this study, the four synthetic VL libraries were combined with the semi-synthetic VH repertoire of ALTHEA Gold Libraries™ to generate a set of fully naïve, general-purpose, libraries called ALTHEA Gold Plus Libraries™. Three out of 24 specific clones for the RBD isolated from the libraries, with affinity in the low nanomolar range and sub-optimal in vitro neutralization in PRNT, were affinity optimized via a method called "Rapid Affinity Maturation" (RAM). The final molecules reached sub-nanomolar neutralization potency, slightly superior to IgG-A7, while the developability profile over the parental molecules was improved. These results demonstrate that general-purpose libraries are a valuable source of potent neutralizing antibodies. Importantly, since general-purpose libraries are "ready-to-use", it could expedite isolation of antibodies for rapidly evolving viruses such as SARS-CoV-2.

Keywords: COVID-19; affinity maturation; phage display; semi-synthetic libraries; therapeutic antibodies.

MeSH terms

  • Animals
  • Antibodies, Neutralizing
  • Antibodies, Viral
  • COVID-19*
  • Humans
  • Immunoglobulin G
  • Mice
  • Mice, Transgenic
  • SARS-CoV-2

Substances

  • Antibodies, Neutralizing
  • Antibodies, Viral
  • Immunoglobulin G

Supplementary concepts

  • SARS-CoV-2 variants

Grants and funding

This work was supported in part by a grant from AMEXID—Secretaría de Relaciones Exteriores Fondo México-Chile (CH05-Anticuerpos neutralizantes para SARS-CoV-2 MEX-CHI). Part of the work was carried out with equipment from the “Laboratorios Nacional para Servicios Especializados de Investigación, Desarrollo e Innovación (I + D + I) para Farmoquímicos y Biotecnológicos”, LANSEIDIFarBiotec-CONACyT.